Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis

Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis

Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a...

Full description

Bibliographic Details
Main Authors: Tamara Quint, Patrick M. Brunner, Christoph Sinz, Irene Steiner, Robin Ristl, Kornelia Vigl, Susanne Kimeswenger, Katharina Neubauer, Detlev Pirkhammer, Martin Zikeli, Wolfram Hoetzenecker, Norbert Reider, Christine Bangert
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Journal of Clinical Medicine
Subjects:
Dupilumab
atopic dermatitis
biologicals
conjunctivitis
rosacea-like folliculitis
Online Access:https://www.mdpi.com/2077-0383/9/4/1241

Internet

https://www.mdpi.com/2077-0383/9/4/1241

Similar Items